Register
Twitter

Research Feed

  • TDI-0132 3/26/12 - We moved this candidate compound known as Gilenya into the development phase.
  • TDI-154 5/7/12 - This small molecule targeting Autophagy/Proteasome entered the vitro validation stage of pipeline.
  • TDI-143 5/7/12 - This biologic targeting endothelial cell dysfunction moved into efficacy studies at TDI.
  • TDI-172 5/7/12 - TDI began to formulate this small molecule immunmodulatory compound for further study.
  • TDI-176 5/7/12 - TDI began to formulate this small molecule targeting the complement pathway for further study (Regensance Partnership).
  • TDI-146 5/7/12 - This protein biologics was removed from the TDI pipeline.
  • TDI-165 5/7/12 - TDI advanced this protein biologic targeting the NMJ info formulation (Neurotune Partnership).
  • TDI-169 5/7/12 - ALS TDI removed this small molecule from its pipeline.
  • TDI-163 5/7/12 - TDI advanced this small molecule targeting Unfolded Protein Response to the formulation stage.
  • TDI-117 5/7/12 - We began efficacy/survival studies with this immunomodulating protein biologic.
  • TDI-166 5/7/12 - In vitro validation experiments began using this small molecule targeting metabolic dysfunction began.
ALS Research

ALS TDI Research Center

What's happening at the #1 ALS research institute in the world? We're testing therapeutics faster and more cost-effectively than anyone else. In fact, we've tested more potential therapeutics than the rest of the ALS research world combined. We work urgently and in collaboration with international biotechnology and pharma companies, academic centers, and other disease organizations to accomplish our mission: to end ALS.

About ALS TDI Research

Microscope

Research Plan

An unbiased, multi-faceted approach that drives our research and delivers results. Find out more >

Process

Research Strategy

The strategy & techniques that will lead us to effective treatments. Learn more >

Team

TDI Super Heroes

A dedicated team that works night and day to end ALS. Meet the TDI Staff >

Hot Topics in Research

Full topic list A-Z >

Clinical Trials

No effective ALS treatments are currently available in the marketplace. But today's clinical trials may lead to tomorrow's cure.

Recent Trial Launches:

View all clinical trials >

Recently Published
from TDI

Research Pipeline

We screen at least 25 therapeutics every year. Here's what's happening in the lab right now:

TDI-144 - 2/10/12 - We moved this small molecule targeting cellular stress into the analysis phase
TDI-143 - 5/7/12 - This biologic targeting endothelial cell dysfunction moved into efficacy studies at TDI.
TDI-177 - 2/10/12 - TDI removed this small molecule compound as a new lead to its pipeline.
TDI-178 - 1/27/12 - This trophin was added as a new lead to the TDI pipeline.
See what else is in the pipeline >

Stats from the Lab

20

complete PK studies each year

200+

drugs screening to date

30

full-time ALS "superheros"